Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone.
This study hereby reports the case of a 19-year old boy with a gamma-delta hepatosplenic T-cell lymphoma (HSTCL). Initial therapy consisted of four cycles of the IEV (Ifosphamide, Epirubicin and Etoposide) scheme. Further treatment strategy was then adapted according to minimal residual disease monitoring by immunophenotypic and T-cell receptor gamma chain gene evaluation. The patient remains in complete clinical, immunological and molecular remission and in good clinical conditions 48 months after diagnosis and 40 months after stopping therapy.
Moleti
Maria Luisa
ML
Division of Haematology, Department of Cellular Biotechnologies and Hematology, University La Spienza, Rome, Italy. moleti@bce.uniroma1.it
Testi
Anna Maria
AM
Giona
Fiorina
F
Amendola
Angela
A
Palumbo
Giovanna
G
Uccini
Stefania
S
Starza
Irene Della
ID
de Propris
Maria Stefania
MS
Guarini
Anna
A
Foà
Robin
R
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D016130:Immunophenotyping; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D018365:Neoplasm, Residual; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000096:biosynthesis*; D012074:Remission Induction; D012680:Sensitivity and Specificity; D013163:Splenomegaly / Q000209:etiology; D016896:Treatment Outcome
D016692:Receptors, Antigen, T-Cell, gamma-delta